Patents by Inventor Herve Geneste

Herve Geneste has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
    Patent number: 9617226
    Abstract: The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: September 4, 2015
    Date of Patent: April 11, 2017
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilfried Braje, Jayne Froggett, Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel van Gaalen
  • FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS
    Publication number: 20170057966
    Abstract: The invention relates to heterocyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
    Type: Application
    Filed: August 26, 2016
    Publication date: March 2, 2017
    Inventors: Udo Lange, Michael Ochse, Elizabeth van der Kam, Jeroen van Bergeijk, Sean Turner, Frank Oellien, Patrick Walleser, Wilhelm Amberg, Wilfried Hornberger, Herve Geneste, Mario Mezler, Charles Hutchins
  • HETEROARYL-SUBSTITUTED 1,3-DIHYDROINDOL-2-ONE DERIVATIVES AND MEDICAMENTS CONTAINING THEM
    Publication number: 20170050959
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivaties can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Application
    Filed: November 7, 2016
    Publication date: February 23, 2017
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • OXINDOLE DERIVATIVES CARRYING A PIPERIDYL-SUBSTITUTED AZETIDINYL SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES
    Publication number: 20170008875
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for treatment of vasopressin-related disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 12, 2017
    Inventors: Hervé GENESTE, Wilfried HORNBERGER, Charles W. HUTCHINS, Katja JANTOS, Andreas KLING, Loic LAPLANCHE, Marcel VAN GAALEN
  • OXINDOLE DERIVATIVES CARRYING AN AMINE-SUBSTITUTED PIPERIDYL-AZETIDINYL SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSINE-RELATED DISEASES
    Publication number: 20170001982
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I) wherein the variables are as defined in the claims and description; to pharmaceutical compositions comprising them, and to their use for the treatment of vasopressin-related disorders.
    Type: Application
    Filed: December 19, 2014
    Publication date: January 5, 2017
    Inventors: Hervé GENESTE, Wilfried HORNBERGER, Charles W. HUTCHINS, Katja JANTOS, Andreas KLING, Loic LAPLANCHE, Marcel VAN GAALEN
  • Oxindole compounds carrying a CO-bound spiro substituent and use thereof for treating vasopressin-related diseases
    Patent number: 9527856
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising compounds I and their use for the treatment of vasopressin-related disorders.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 27, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Wilfried Braje, Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Claudia Krack, Marcel Van Gaalen
  • CARBAMATE-SUBSTITUTED OXINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT DISEASES
    Publication number: 20160362394
    Abstract: The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
    Type: Application
    Filed: August 23, 2016
    Publication date: December 15, 2016
    Inventors: Astrid Netz, Thorsten Oost, Hervé Geneste, Wilfried Braje, Wolfgang Wernet, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch
  • Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
    Patent number: 9487505
    Abstract: The present invention relates to novel 1,3-dihydroindol-2-one (oxindole) derivatives of the formula (I) in which A, R3, R4, R5, R6 and R7 are defined according to claim 1, and to medicaments containing them for the treatment of diseases. In particular, the novel oxindole derivatives can be used for the control and/or prophylaxis of various vasopressin-dependent or oxytocin-dependent diseases.
    Type: Grant
    Filed: September 25, 2013
    Date of Patent: November 8, 2016
    Assignees: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Wilfried Lubisch, Wilfried Hornberger, Thorsten K. Oost, Daryl Richard Sauer, Liliane Unger, Wolfgang Wernet, Hervé Geneste
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20160318871
    Abstract: The present invention relates to compounds which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: July 11, 2016
    Publication date: November 3, 2016
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Jürgen Dinges, Clarissa Jakob
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9475808
    Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables Het, A, X, Y, Z, R1, R2, R3, R4, R5 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: September 15, 2015
    Date of Patent: October 25, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9464085
    Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof. where in formula I the variables R1, R2, R3, R4 and R5 are as defined in the claims and where X is C—R6 or N, Y is C—R7 or N, where R6 and R7 are, inter alia, hydrogen, halogen, alkoxy, haloalkoxy and the like. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: August 15, 2013
    Date of Patent: October 11, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Clarissa Jakob
  • Carbamate-substituted oxindole derivatives and use thereof for the treatment of vasopressin-dependent diseases
    Patent number: 9422264
    Abstract: The present invention relates to novel carbamate-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: August 23, 2016
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Astrid Netz, Thorsten Oost, Hervé Geneste, Wilfried Braje, Wolfgang Wernet, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch
  • Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses
    Patent number: 9403796
    Abstract: The present invention relates to novel amidomethyl-substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-dependent disorders.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 2, 2016
    Assignee: ABBVIE DEUTSCHLAND GMBH & CO. KG
    Inventors: Thorsten Oost, Astrid Netz, Hervé Geneste, Wilfried Braje, Wolfgang Wernet, Liliane Unger, Wilfried Hornberger, Wilfried Lubisch
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9388180
    Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: July 12, 2016
    Assignees: AbbVie Inc., Abbott GmbH & Co. KG
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Clarissa Jakob, Maricel Torrent
  • OXINDOLE DERIVATIVES CARRYING AN OXETANE SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
    Publication number: 20160168135
    Abstract: The present invention relates to novel substituted oxindole derivatives, pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders.
    Type: Application
    Filed: February 22, 2016
    Publication date: June 16, 2016
    Inventors: Katja Jantos, Wilfried Braje, Hervé Geneste, Andreas Kling, Liliane Unger, Berthold Behl, Marcel van Gaalen, Wilfried Hornberger, Loic Laplanche, Silke Weber
  • NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A
    Publication number: 20160137668
    Abstract: The present invention relates to novel compounds of the formula I which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Application
    Filed: January 18, 2016
    Publication date: May 19, 2016
    Inventors: Hervé GENESTE, Michael OCHSE, Karla DRESCHER, Sean TURNER, Berthold BEHL, Loic LAPLANCHE, Jürgen DINGES, Clarissa JAKOB, Lawrence BLACK
  • FUSED HETEROCYCLIC OR CARBOCYCLIC COMPOUNDS CARRYING A SUBSTITUTED CYCLOALIPHATIC RADICAL AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES
    Publication number: 20160068494
    Abstract: The present invention relates to novel fused heterocyclic or carbocyclic compounds of formula I wherein the variables are as defined in the claims and the description. The invention further relates to pharmaceutical compositions comprising these compounds, and to their use for the treatment of vasopressin-related disorders.
    Type: Application
    Filed: September 4, 2015
    Publication date: March 10, 2016
    Inventors: Wilfried Braje, Jayne Froggett, Hervé Geneste, Wilfried Hornberger, Katja Jantos, Andreas Kling, Marcel van Gaalen
  • Substituted isoquinolines and phthalazines as inhibitors of phosphodiesterase type 10A
    Patent number: 9273068
    Abstract: The present invention relates to novel compounds of the formula (I), wherein Het, A, Q, X1, X2, X3, R1 and R2 are defined in the specification, which are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: October 29, 2012
    Date of Patent: March 1, 2016
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Hervé Geneste, Michael Ochse, Karla Drescher, Sean Turner, Berthold Behl, Loic Laplanche, Jürgen Dinges, Clarissa Jakob, Lawrence Black
  • Oxindole derivatives carrying an oxetane substituent and use thereof for treating vasopressine-related diseases
    Patent number: 9273036
    Abstract: The present invention relates to novel substituted oxindole derivatives of formula (I), pharmaceutical compositions comprising them, and their use for the treatment of vasopressin-related disorders
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 1, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Katja Jantos, Wilfred Braje, Herve Geneste, Andreas Kling, Liliane Unger, Berthold Behl, Marcel van Gaalen, Wilfried Hornberger, Loic Laplanche, Silke Weber
  • Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mGlu2 receptor)
    Patent number: 9242933
    Abstract: The present invention relates to heterocyclic compounds which are positive modulators of metabotropic glutamate receptor. The present invention also relates to the use of these compounds for preparing a pharmaceutical composition and to a method of treating a medical disorder, selected from neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Grant
    Filed: May 23, 2008
    Date of Patent: January 26, 2016
    Assignee: AbbVie Deutschland GmbH & Co. KG
    Inventors: Herve Geneste, Daryl Sauer, Wilfried Braje, Wilhelm Amberg, Mario Mezler, Margaretha Henrica Maria Bakker